Also up early Thursday: Bellicum and Novocure.
The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.
H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.